+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Etanercept"

Market Spotlight: Psoriatic Arthritis - Product Thumbnail Image

Market Spotlight: Psoriatic Arthritis

  • Report
  • September 2020
  • 65 Pages
  • Global
From
Alzheimer Disease - New Drugs, Markets and Companies - Product Thumbnail Image

Alzheimer Disease - New Drugs, Markets and Companies

  • Report
  • November 2021
  • 575 Pages
  • Global
From
Therapeutic Fc-Fusion Proteins. Edition No. 1 - Product Thumbnail Image

Therapeutic Fc-Fusion Proteins. Edition No. 1

  • Book
  • February 2014
  • 400 Pages
Loading Indicator

Etanercept is a biologic drug used to treat immune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is a recombinant fusion protein that works by blocking the action of tumor necrosis factor (TNF), a protein involved in inflammation. Etanercept is administered by subcutaneous injection and is available in both brand name and generic forms. Etanercept is a widely used drug in the treatment of immune disorders, and is often prescribed in combination with other medications. It is generally well tolerated, with the most common side effects being injection site reactions, headache, and upper respiratory tract infections. The etanercept market is highly competitive, with several major players. These include Amgen, Pfizer, AbbVie, and Johnson & Johnson. Other companies in the market include Biogen, Merck, and Novartis. Show Less Read more